Join us online for Absci’s R&D Day 2024 on Thursday, December 12th at 9:00 AM ET. Hear the latest updates on our platform, pipeline, and partnerships from the Absci team and special guests. Sign up to watch the live webcast here: https://lnkd.in/gAB6rxWy #AI #Biologics #DrugDiscovery
关于我们
Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation? platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to learn, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Our vision is to deliver breakthrough therapeutics at the click of a button, for everyone.
- 网站
-
https://www.absci.com
Absci的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Vancouver，Washington
- 类型
- 上市公司
- 创立
- 2011
- 领域
- generative AI、synthetic biology、biologics、drug discovery、antibody development、artificial intelligence、pharmaceuticals和biotechnology
地点
-
主要
获取路线
US，Washington，Vancouver，98683
Absci员工
动态
-
Absci Founder and CEO Sean McClain joined Web Summit 2024 to discuss the present and future of AI Drug Discovery and why high-quality, high-throughput data is critical to unlock AI’s potential to bring better medicines to patients, faster. #AI #Biologics #DrugDiscovery
-
Our Founder and CEO Sean McClain recently spoke with Genetic Engineering & Biotechnology News to discuss some of our exciting recent updates. Learn about our new collaboration with Twist Bioscience, the continued development of our internal pipeline, and more in this piece from Alex Philippidis. Read it here: https://lnkd.in/gn8nH_SW #AI #Biologics #DrugDiscovery
Supplier-Turned-Partner: Twist Joins Absci in AI Antibody Collaboration Emily Leproust, PhD, Twist Bioscience's CEO and co-founder and Absci founder and CEO Sean McClain spoke with GEN Edge's Alex Philippidis.
-
We are excited to welcome Anders Kassow as Head of Intellectual Property! Help us give Anders a warm welcome with a like or a comment below!?? #AI #Biologics #DrugDiscovery
-
-
Our Founder & CEO Sean McClain spoke with STAT's Brittany Trang to discuss the growing field of AI protein design and how Absci’s de novo AI has shown early proof-points and successes in designing novel therapeutic antibodies.? Read more here: https://lnkd.in/er_54XzE #AI #Biologics #DrugDiscovery
7 companies to watch in AI protein design
https://www.statnews.com
-
Absci Founder & CEO Sean McClain and CIO Andreas Busch recently joined ARK Investment Management LLC's For Your Information Podcast to talk about AI’s impact on drug discovery and the early proof points from our work at Absci. #AI #Biologics #DrugDiscovery
"We’re solving the design problem with AI, unlocking biology that was previously undruggable." - Sean McClain, Founder & CEO of Absci https://arkinv.st/3Cb1bIH
The Future Of AI And Drug Development: Insights From Absci’s Sean McClain And Andreas Busch
ark-invest.com
-
Join us this week at PEGS Europe where Absci’s Amir S. and Douglas Ganini da Silva will be speaking about how we used AI to create novel, differentiated biologics. Tune in to our presentation “Development of ABS-101: A Potential Best-in-Class Anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease” on Nov 6th at 5:15 PM in the Machine Learning Stream. Learn more here: https://lnkd.in/ghBNMEBp #AI #Biologics #DrugDiscovery
-
-
Absci转发了
Andreas Busch and I had a great conversation on ARK Investment Management LLC’s FYI podcast with Brett Winton and Charles Campbell Roberts about AI’s impact on drug discovery. We explored why a data-first approach is essential and how a multilingual team—experts in AI, biology, and drug discovery—drives breakthroughs that could lead to better patient outcomes. For anyone curious about where AI and medicine intersect, tune in!
The Future Of AI And Drug Development: Insights From Absci’s Sean McClain And Andreas Busch
ark-invest.com
-
We are excited to announce our new collaboration with Twist Bioscience, which brings together Absci’s Generative AI drug creation platform with Twist’s DNA synthesis platform to accelerate the design of a novel therapeutic antibody. Read more here: https://lnkd.in/gUezC29s #AI #Biologics #DrugDiscovery
-
-
We recently shared data on ABS-101, a potential best-in-class anti-TL1A antibody for the treatment of IBD, at the Festival of Biologics Europe. Download our poster to learn how we used AI to create ABS-101 and engineer-in an optimized target product profile. Download here: https://lnkd.in/gZkfkTGa #AI #Biologics #DrugDiscovery
-